AC-262

AC-262 is a non-steroidal selective androgen receptor modulator (SARM) with partial agonist activity at the androgen receptor. Originally developed by ACADIA Pharmaceuticals for research into muscle and bone conditions, AC-262 is widely used as a tool compound in androgen receptor research, partial agonism studies, and investigations into lower-potency tissue-selective androgens.AC-262,536 (commonly referred to as AC-262) is a selective androgen receptor modulator (SARM) that was developed by ACADIA Pharmaceuticals as part of their research into tissue-selective androgens. Unlike full agonist SARMs, AC-262 functions as a partial agonist at the androgen receptor, demonstrating approximately 66% of the anabolic activity of testosterone in preclinical models while exhibiting significantly reduced androgenic effects.

As a SARM with partial agonist properties, AC-262 offers researchers a unique profile for studying the continuum between full and partial androgen receptor activation. This characteristic makes it particularly valuable for investigating dose-response relationships, receptor activation dynamics, and the potential for developing compounds that provide anabolic benefits with reduced androgenic side effects.

AC-262 Name and Classification

AC-262,536 is identified by its research designation and is sometimes abbreviated as AC-262 in scientific literature. The compound belongs to the class of selective androgen receptor modulators and represents a partial agonist subtype within this class.

AC-262 was originally developed by ACADIA Pharmaceuticals as part of a broader program investigating novel approaches to androgen receptor modulation. The compound's partial agonist profile distinguishes it from stronger full agonist SARMs like LGD-4033 or S23.

AC-262 Mechanism of Action

AC-262 functions by binding to androgen receptors and acting as a partial agonist, producing submaximal activation compared to full agonists like testosterone or dihydrotestosterone. This partial agonism results in anabolic effects that are present but less pronounced than those of full agonist SARMs.

Key mechanistic features include:

• Partial agonist activity at approximately 66% of testosterone's efficacy
• Androgen receptor binding with moderate affinity
• Tissue-selective effects with preferential activity in muscle and bone
• Reduced androgenic potency compared to full agonist compounds
• Non-aromatizing properties - does not convert to estrogen

In experimental models, AC-262 demonstrates the ability to produce anabolic effects in muscle tissue while exhibiting minimal androgenic activity in prostate tissue. The partial agonist profile may result in reduced suppression of endogenous testosterone production compared to stronger SARMs, though this requires further investigation.

AC-262 Benefits in Research

In preclinical research settings, AC-262 has been studied for its effects on muscle, bone, and cognitive function. Published animal studies suggest that AC-262 may:

• Increase muscle mass through partial androgen receptor activation
• Improve bone mineral density and bone strength parameters
• Demonstrate neuroprotective effects in some cognitive models
• Produce milder anabolic effects suitable for studying partial agonism
• Exhibit favorable tissue selectivity with minimal prostate stimulation
• Provide research model for lower-intensity androgen receptor activation

These findings from controlled experimental models help researchers understand partial agonist activity at the androgen receptor and explore the therapeutic potential of compounds with submaximal receptor activation profiles.

AC-262 Dosage in Experimental Studies

Available data on AC-262 dosage comes primarily from preclinical animal research. Published studies report varying protocols depending on research objectives and experimental models used.

Typical experimental dosing ranges:

• 10-30 mg/kg administered once daily in rodent models
• Higher doses required compared to full agonist SARMs due to partial agonist profile
• Chronic administration protocols ranging from several weeks to months
• Dose-response studies to establish efficacy thresholds

Dosing considerations in research:

• Oral administration appears feasible based on preclinical data
• Once or twice-daily dosing used depending on pharmacokinetic profile
• Higher doses needed to achieve comparable effects to full agonist SARMs
• Duration of administration varies based on endpoints measured

The AC-262 dosage used in research directly impacts the degree of anabolic effects achieved and the compound's tissue selectivity profile. Due to its partial agonist nature, AC-262 typically requires higher doses than full agonist SARMs to produce measurable anabolic effects, making dose optimization an important consideration in experimental design.

AC-262 Side Effects in Research Models

Because AC-262 is a partial agonist SARM with relatively mild activity, AC-262 side effects observed in research models are generally less pronounced than those of stronger SARMs. In preclinical studies, researchers monitor for:

Hormonal effects:

• Minimal to mild testosterone suppression - significantly less than full agonist SARMs
• Reduced impact on LH and FSH due to partial agonist profile
• Lower risk of significant HPG axis disruption at moderate doses

Physical and metabolic observations:

• Generally mild side effect profile in animal studies
• Minimal prostate tissue stimulation demonstrating tissue selectivity
• No significant liver toxicity reported in preclinical research
• Favorable tolerability compared to stronger androgens

Androgenic effects:

• Reduced androgenic side effects such as aggression or behavioral changes
• Minimal virilization effects in appropriate models
• Limited impact on sebaceous gland activity

Cognitive and neurological observations:

• Potential neuroprotective effects noted in some research contexts
• No significant adverse neurological effects in preclinical studies

The AC-262 side effects profile in preclinical research suggests a milder compound compared to full agonist SARMs. The partial agonist activity appears to result in reduced suppression of endogenous hormones and fewer androgenic side effects, though comprehensive safety data remains limited. Understanding this favorable side effect profile makes AC-262 valuable for research into compounds that provide anabolic benefits with improved tolerability.

AC-262 and Cognitive Research

An interesting aspect of AC-262 research involves investigation of its effects on cognitive function and neuroprotection. Some preclinical studies have examined AC-262's potential neuroprotective properties and effects on learning and memory in animal models. While this research is preliminary, it suggests that selective androgen receptor modulators may have applications beyond muscle and bone, contributing to broader understanding of androgen receptor function in the central nervous system.

Oral Administration in Research

AC-262 has been administered orally in preclinical research protocols, though detailed pharmacokinetic data remains limited in published literature. The compound appears to have acceptable bioavailability for oral dosing in animal studies, making this route practical for research applications.

The oral route allows researchers to examine chronic effects on muscle, bone, and other tissues over extended treatment periods typical of SARM research protocols.

Human Clinical Trials

AC-262 has not advanced to human clinical trials. All available research data comes from preclinical animal studies. While the compound demonstrates interesting partial agonist properties in experimental models, human safety, efficacy, and pharmacokinetic data do not exist.

Current research remains at the preclinical level, with AC-262 serving primarily as a tool compound for understanding partial agonist activity at the androgen receptor and exploring lower-intensity SARM profiles.

Why You Should Buy AC-262 from Sarmful

If you are looking to buy AC-262 for research purposes, we offer AC-262 for sale in liquid form, prepared to support consistent and reliable experimental work.

When you buy AC-262 from Sarmful, you benefit from:

• Third-party lab testing and in-house verification for purity and concentration
• EU and US domestic shipping for reliable delivery to your research facility
• Convenient payment methods designed for seamless research procurement
• Research-grade quality formulated to meet the standards of serious laboratory work